Tweet Tracking: A Must For Companies’ Adverse Event Oversight?
This article was originally published in The Pink Sheet Daily
Regulatory experts disagree on how actively device and drug companies should be monitoring social media sites for information on adverse events.
You may also be interested in...
In the absence of clear policy from the agency, GSK keeps careful eyes on Facebook, but experts disagree on the extent to which drug companies are required to actively monitor social media sites.
FDA draft guidance weighs in on web communications, saying that firms must answer off-label-information questions privately, even if the questions arise in a public online forum.
The US Congress this week agreed to keep the FDA and other government agencies funded at fiscal-year 2019 levels, extending the continuing resolution another four weeks until 20 December.